ASL Metabolically Regulates Tyrosine Hydroxylase in the Nucleus Locus Coeruleus

Shaul Lerner, Elmira Anderzhanova, Sima Verbitsky, Raya Eilam, Yael Kuperman, Michael Tsoory, Yuri Kuznetsov, Alexander Brandis, Tevie Mehlman, Ram Mazkereth, UCDC Neuropsychologists, Robert McCarter, Menahem Segal, Sandesh C S Nagamani, Alon Chen, Ayelet Erez, Fabienne Dietrich Alber, Talin Babikian, Heidi Bender, Christopher Boys, David Breiger, Corinna Buerger, Peter Burgard, Mina Nguyen-Driver, Benjamin Goodlett, Elizabeth Kerr, Casey Krueger, Eva Mamak, Jacqueline H Sanz, David Schwartz, Susan Caudle, Arianna Stefanos, Rachel Tangen, Magdalena Walter, Susan Waisbren, Greta Wilkening, Shaul Lerner, Elmira Anderzhanova, Sima Verbitsky, Raya Eilam, Yael Kuperman, Michael Tsoory, Yuri Kuznetsov, Alexander Brandis, Tevie Mehlman, Ram Mazkereth, UCDC Neuropsychologists, Robert McCarter, Menahem Segal, Sandesh C S Nagamani, Alon Chen, Ayelet Erez, Fabienne Dietrich Alber, Talin Babikian, Heidi Bender, Christopher Boys, David Breiger, Corinna Buerger, Peter Burgard, Mina Nguyen-Driver, Benjamin Goodlett, Elizabeth Kerr, Casey Krueger, Eva Mamak, Jacqueline H Sanz, David Schwartz, Susan Caudle, Arianna Stefanos, Rachel Tangen, Magdalena Walter, Susan Waisbren, Greta Wilkening

Abstract

Patients with germline mutations in the urea-cycle enzyme argininosuccinate lyase (ASL) are at risk for developing neurobehavioral and cognitive deficits. We find that ASL is prominently expressed in the nucleus locus coeruleus (LC), the central source of norepinephrine. Using natural history data, we show that individuals with ASL deficiency are at risk for developing attention deficits. By generating LC-ASL-conditional knockout (cKO) mice, we further demonstrate altered response to stressful stimuli with increased seizure reactivity in LC-ASL-cKO mice. Depletion of ASL in LC neurons leads to reduced amount and activity of tyrosine hydroxylase (TH) and to decreased catecholamines synthesis, due to decreased nitric oxide (NO) signaling. NO donors normalize catecholamine levels in the LC, seizure sensitivity, and the stress response in LC-ASL-cKO mice. Our data emphasize ASL importance for the metabolic regulation of LC function with translational relevance for ASL deficiency (ASLD) patients as well as for LC-related pathologies.

Keywords: ASL; locus coeruleus; nitric oxide; stress response; tyrosine hydroxylase; urea cycle disorders.

Conflict of interest statement

The authors declare no competing interests.

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
ASL Is Highly Expressed in the LC and Regulates TH Levels (A) Left: in situ hybridization with Asl anti-sense mRNA probe showing in purple Asl prominent expression in the LC. Right: scheme of brain stem coronal section is shown. LC region is highlighted in purple (image adapted from The Mouse Brain Atlas). (B) Immunostaining of mouse brainstem for Asl (left, red), TH (center, green), and their merged co-localization (right). (C) Immunostaining of human brainstem for ASL (left, red), TH (center, green), and their merged co-localization (right). (D and E) Quantification of Asl mRNA (D) and TH mRNA (E) isolated by laser microdissection from the LC of Aslf/f;TH Cre+/− and from Aslf/f control mice as measured by RT-PCR with specific TaqMan probes (n = 100 cells from 7 animals). (F) Immunohistochemistry quantification of TH protein normalized to cells number (n = 4 in each group). (G) Quantification of western blots for TH levels in LC regions taken by punch biopsies (n = 4 in each group). The bottom panels of (F) and (G) show representative images for each detection method, respectively. Data represent mean ± SEM (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, not significant). See Tables S1, S2, and S3 for RNA sequencing, ingenuity pathway analysis, and proteomic analysis, respectively.
Figure 2
Figure 2
ASL Regulates TH Levels by Regulating NO Availability (A) NO levels measurement using DAF-FM probe demonstrates significantly reduced NO levels in the LC of Aslf/f,Ai9f/f;TH Cre+/− mice as compared to Ai9f/f;TH Cre+/− control mice (each experiment was performed with pair of control and Aslf/f,Ai9f/f;TH Cre+/− mice; n = 3). (B) Knockdown of ASL in SH-SY5Y neurons using three different lentiviral ASL-shRNA clones associates with downregulation in TH mRNA levels. (C) shASL SH-SY5Y neurons have significantly reduced nitrosylation of GAPDH (left) and of TH (right; measurement was performed ≥3 times). (D) NO donors’ supplementation to SH-SY5Y neurons rescues the differences in GAPDH (left) and TH (right) nitrosylation between shASL and shGFP control neurons. (E) Treatment of shASL neurons with NO donors normalizes TH mRNA levels to that of shGFP control neurons (n ≥ 3; one-way ANOVA with Bonferroni). Data represent mean ± SEM (∗p < 0.05; ∗∗p < 0.01). See also Figure S3.
Figure 3
Figure 3
ASL Deficiency Associates with Decreased Catecholamine Synthesis (A) Measurement of LC catecholamine levels show alterations in quantity and in turnover rates in both dopamine (left) and in norepinephrine (right), in Aslf/f;TH Cre+/− as compared to Aslf/f control mice (n ≥ 10 mice in each group). (B) Measurements of norepinephrine levels in the hippocampus following stress show decreased elevation in Aslf/f;TH Cre+/− as compared to Aslf/f control mice (n ≥ 9 mice in each group). (C) Measurements of LC norepinephrine levels of mice treated with NaNO2 show no difference between Aslf/f;TH Cre+/− and Aslf/f control mice (n ≥ 5 mice in each group). Data represent mean ± SEM (non-repeated-measures two-way ANOVA with Bonferroni post hoc t tests; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
Figure 4
Figure 4
ASL Deficiency in the LC Associates with Increased Firing from LC Neurons (A) Representative recordings of spontaneous action potentials of LC neurons. Upper panel —Aslf/f control, showing typical inter-spike interval variability; lower panel—Aslf/f;TH Cre+/− (frequency 7.9 ± 0.6 Hz in Aslf/f control; 13.8 ± 2.0 Hz in Aslf/f;TH Cre+/−; p < 0.01). (B) Averaged normalized inter-spike interval (ISI) histograms. (Left) Aslf/f control n = 14 is shown; (right) Aslf/f;TH Cre+/− n = 15 cells are shown; red, gamma distribution probability density function fit with shape parameters 26 and 60 and scale parameters 5.9 and 1.7, respectively. ISI distributions from single recordings were also fit with gamma distribution (data not shown) with shape parameters 31 ± 6 and 122 ± 37 (p < 0.03) and scale parameters 8.4 ± 2.7 and 2.4 ± 0.8 (p < 0.04) in Aslf/f control and Aslf/f;TH Cre+/−, respectively. (C) Spiking frequency presented as mean ISI (left; 144 ± 17 ms in Aslf/f control [n = 14 cells from 3 animals] and 93 ± 13 ms in Aslf/f;TH Cre+/− [n = 15 cells from 3 animals] p < 0.03) and SEM. ISI as a measure of ISI variability (right; SEM ISI 33 ± 6 ms in Aslf/f control and 14 ± 3 ms in Aslf/f;TH Cre+/−; p < 0.02). (D) Examples for averaged spike (first 10 spikes from a recording per cell), showing the “landmarks” used for analyzing the spike shape (red asterisks: spike threshold; spike peak; and after-hyperpolarization). Red line, AHP recovery slope. (E) Firing frequency and after-hyperpolarization (AHP) recovery slope scatterplot and per-cell linear regression plot: Ct ● y = 15x + 5; r2 = 0.25; dashed line; cKO ♦ y = 61x − 2; r2 = 0.79; solid line. (F) After hyperpolarization current properties; left to right, amplitude (ahpAmpl −19.5 ± 0.7 mV n = 13 and −19.0 ± 1.0 mV n = 14; n.s.) and recovery slope (ahpSlope 0.18 ± 0.01 mV/ms n = 13 and 0.23 ± 0.02 mV/ms n = 14; p Aslf/f;TH Cre+/− group, this slope is correlated with firing frequency (data not shown; correlation coefficient 0.79; p < 0.001; Pearson correlation), whereas in the Aslf/f control cells, this correlation was not observed (0.25; p = 0.41). Other passive and active properties of LC neurons were not significantly different between the groups (data not shown; resting membrane potential −48.9 ± 0.7 mV n = 12 and −48.6 ± 0.9 mV n = 15; input resistance 113 ± 7 MOhm n = 13 and 121 ± 11 MOhm n = 15; spike threshold −39.8 ± 0.9 mV n = 12 and −38.6 ± 1.0 mV n = 15; spike amplitude 83.1 ± 2.2 mV n = 14 and 86.1 ± 2.5 mV n = 15; spike width 2.09 ± 0.08 ms n = 14 and 2.04 ± 0.06 ms n = 15 in Aslf/f control and Aslf/f;TH Cre+/−, respectively).
Figure 5
Figure 5
Phenotypic Consequences of ASL Deficiency in LC (A) Measured mean arterial pressure (MAP) levels following induction of acute stress by exposure to intruder mice. The increase in blood pressure levels following stress is higher in Aslf/f;TH Cre+/− mice and requires a longer recovery time as compared to Aslf/f control and to endothelial-ASL cKO mice (n ≥ 8 in each group; repeated-measures two-way ANOVA with Holm-Sidak’s post hoc t tests). (B) Continuous blood pressure measurement during the first 3 h after stress induction demonstrates a significantly higher blood pressure in Aslf/f;TH Cre+/− mice as compared to Aslf/f control mice (n ≥ 8 in each group). (C and D) Open-field test locomotor evaluation. Following stressful stimuli, Aslf/f;TH Cre+/− mice present increase locomotor activity as indicated in distance (C) and speed (D), in comparison to Aslf/f control mice. Following treatment with NO donors, Aslf/f;TH Cre+/− mice response to stressful stimuli is similar to that of Aslf/f control mice (n ≥ 11 in each group; non-repeated-measures two-way ANOVA with Bonferroni post hoc t tests). (E) Seizure score after injection of 50 mg/kg PTZ is higher in Aslf/f;TH Cre+/− mice as compared to Aslf/f control mice. Following treatment with NO donor, there was no significant difference in the seizure reaction to injection between the two genotypes (n = 6 in each group). (F) Kaplan Meier estimator presenting the probability of mice to develop myoclonic jerks from the time of PTZ injection. Aslf/f;TH Cre+/− mice have more than 4-fold chance of developing myoclonic jerks as compared to Aslf/f control mice. Data represent mean ± SEM (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001). See also Figure S4.

References

    1. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
    1. Anders S., Pyl P.T., Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169.
    1. Anderzhanova E.A., Bächli H., Buneeva O.A., Narkevich V.B., Medvedev A.E., Thoeringer C.K., Wotjak C.T., Kudrin V.S. Strain differences in profiles of dopaminergic neurotransmission in the prefrontal cortex of the BALB/C vs. C57Bl/6 mice: consequences of stress and afobazole. Eur. J. Pharmacol. 2013;708:95–104.
    1. Baruteau J., Jameson E., Morris A.A., Chakrapani A., Santra S., Vijay S., Kocadag H., Beesley C.E., Grunewald S., Murphy E. Expanding the phenotype in argininosuccinic aciduria: need for new therapies. J. Inherit. Metab. Dis. 2017;40:357–368.
    1. Baruteau J., Perocheau D.P., Hanley J., Lorvellec M., Rocha-Ferreira E., Karda R., Ng J., Suff N., Diaz J.A., Rahim A.A. Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nat. Commun. 2018;9:3505.
    1. Baruteau J., Diez-Fernandez C., Lerner S., Ranucci G., Gissen P., Dionisi-Vici C., Nagamani S., Erez A., Häberle J. Argininosuccinic aciduria: recent pathophysiological insights and therapeutic prospects. J. Inherit. Metab. Dis. 2019 Published online February 5, 2019.
    1. Blecher-Gonen R., Barnett-Itzhaki Z., Jaitin D., Amann-Zalcenstein D., Lara-Astiaso D., Amit I. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat. Protoc. 2013;8:539–554.
    1. Braissant O. Measurement of nitric oxide-related enzymes in the brain by in situ hybridization. Methods Mol. Biol. 2004;279:113–124.
    1. Bredt D.S., Hwang P.M., Snyder S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768–770.
    1. Brunetti-Pierri N., Erez A., Shchelochkov O., Craigen W., Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol. Genet. Metab. 2009;98:195–197.
    1. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007;8:766–775.
    1. Carter M.E., Yizhar O., Chikahisa S., Nguyen H., Adamantidis A., Nishino S., Deisseroth K., de Lecea L. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat. Neurosci. 2010;13:1526–1533.
    1. Chachua T., Bilanishvili I., Khizanishvili N., Nanobashvili Z. Noradrenergic modulation of seizure activity. Georgian Med. News. 2010:34–39.
    1. Darcq E., Kieffer B.L. PI3K signaling in the locus coeruleus: a new molecular pathway for ADHD research. EMBO Mol. Med. 2015;7:859–861.
    1. Elam M., Yao T., Svensson T.H., Thoren P. Regulation of locus coeruleus neurons and splanchnic, sympathetic nerves by cardiovascular afferents. Brain Res. 1984;290:281–287.
    1. Erez A., DeBerardinis R.J. Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat. Rev. Cancer. 2015;15:440–448.
    1. Erez A., Nagamani S.C., Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am. J. Med. Genet. C. Semin. Med. Genet. 2011;157C:45–53.
    1. Erez A., Nagamani S.C., Shchelochkov O.A., Premkumar M.H., Campeau P.M., Chen Y., Garg H.K., Li L., Mian A., Bertin T.K. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat. Med. 2011;17:1619–1626.
    1. Feodorova Y., Koch M., Bultman S., Michalakis S., Solovei I. Quick and reliable method for retina dissociation and separation of rod photoreceptor perikarya from adult mice. MethodsX. 2015;2:39–46.
    1. Ficicioglu C., Mandell R., Shih V.E. Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening. Mol. Genet. Metab. 2009;98:273–277.
    1. Fornai F., Ruffoli R., Giorgi F.S., Paparelli A. The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation. Eur. J. Neurosci. 2011;33:2169–2178.
    1. Forrester M.T., Thompson J.W., Foster M.W., Nogueira L., Moseley M.A., Stamler J.S. Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture. Nat. Biotechnol. 2009;27:557–559.
    1. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med. 2009;15:391–404.
    1. Giorgi F.S., Ferrucci M., Lazzeri G., Pizzanelli C., Lenzi P., Alessandrl M.G., Murri L., Fornai F. A damage to locus coeruleus neurons converts sporadic seizures into self-sustaining limbic status epilepticus. Eur. J. Neurosci. 2003;17:2593–2601.
    1. Gladwin M.T., Crawford J.H., Patel R.P. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic. Biol. Med. 2004;36:707–717.
    1. Guix F.X., Uribesalgo I., Coma M., Muñoz F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 2005;76:126–152.
    1. Harraz M.M., Snyder S.H. Nitric oxide-GAPDH transcriptional signaling mediates behavioral actions of cocaine. CNS Neurol. Disord. Drug Targets. 2015;14:757–763.
    1. Huemer M., Carvalho D.R., Brum J.M., Ünal Ö., Coskun T., Weisfeld-Adams J.D., Schrager N.L., Scholl-Bürgi S., Schlune A., Donner M.G. Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency. J. Inherit. Metab. Dis. 2016;39:331–340.
    1. Huetteman D.A., Bogie H. Direct blood pressure monitoring in laboratory rodents via implantable radio telemetry. Methods Mol. Biol. 2009;573:57–73.
    1. Janitzky K., Lippert M.T., Engelhorn A., Tegtmeier J., Goldschmidt J., Heinze H.J., Ohl F.W. Optogenetic silencing of locus coeruleus activity in mice impairs cognitive flexibility in an attentional set-shifting task. Front. Behav. Neurosci. 2015;9:286.
    1. Kho J., Tian X., Wong W.T., Bertin T., Jiang M.M., Chen S., Jin Z., Shchelochkov O.A., Burrage L.C., Reddy A.K. Argininosuccinate lyase deficiency causes an endothelial-dependent form of hypertension. Am. J. Hum. Genet. 2018;103:276–287.
    1. Kim D., Pertea G., Trapnell C., Pimentel H., Kelley R., Salzberg S.L. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
    1. Kleijer W.J., Garritsen V.H., Linnebank M., Mooyer P., Huijmans J.G., Mustonen A., Simola K.O., Arslan-Kirchner M., Battini R., Briones P. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J. Inherit. Metab. Dis. 2002;25:399–410.
    1. Kline R.L., Zhang S., Farr O.M., Hu S., Zaborszky L., Samanez-Larkin G.R., Li C.S. The effects of methylphenidate on resting-state functional connectivity of the basal nucleus of meynert, locus coeruleus, and ventral tegmental area in healthy adults. Front. Hum. Neurosci. 2016;10:149.
    1. Kölker S., Garcia-Cazorla A., Valayannopoulos V., Lund A.M., Burlina A.B., Sykut-Cegielska J., Wijburg F.A., Teles E.L., Zeman J., Dionisi-Vici C. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J. Inherit. Metab. Dis. 2015;38:1041–1057.
    1. Kölker S., Valayannopoulos V., Burlina A.B., Sykut-Cegielska J., Wijburg F.A., Teles E.L., Zeman J., Dionisi-Vici C., Barić I., Karall D. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J. Inherit. Metab. Dis. 2015;38:1059–1074.
    1. Korosi A., Veening J.G., Kozicz T., Henckens M., Dederen J., Groenink L., van der Gugten J., Olivier B., Roubos E.W. Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res. 2006;1072:46–54.
    1. Kovalevich J., Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol. Biol. 2013;1078:9–21.
    1. Lågas P.A., Ruokonen A. Late onset argininosuccinic aciduria in a paranoid retardate. Biol. Psychiatry. 1991;30:1229–1232.
    1. Madisen L., Zwingman T.A., Sunkin S.M., Oh S.W., Zariwala H.A., Gu H., Ng L.L., Palmiter R.D., Hawrylycz M.J., Jones A.R. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 2010;13:133–140.
    1. McCall J.G., Al-Hasani R., Siuda E.R., Hong D.Y., Norris A.J., Ford C.P., Bruchas M.R. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron. 2015;87:605–620.
    1. Mercimek-Mahmutoglu S., Moeslinger D., Häberle J., Engel K., Herle M., Strobl M.W., Scheibenreiter S., Muehl A., Stöckler-Ipsiroglu S. Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol. Genet. Metab. 2010;100:24–28.
    1. Mori M., Gotoh T. Arginine metabolic enzymes, nitric oxide and infection. J. Nutr. 2004;134(10, Suppl) 2820S–2825S, discussion 2853S.
    1. Nagababu E., Ramasamy S., Abernethy D.R., Rifkind J.M. Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. J. Biol. Chem. 2003;278:46349–46356.
    1. Nagamani S.C.S., Erez A., Lee B. Argininosuccinate lyase deficiency. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., Amemiya A., editors. Volume R. University of Washington; 2011. (GeneReviews).
    1. Nagamani S.C., Campeau P.M., Shchelochkov O.A., Premkumar M.H., Guse K., Brunetti-Pierri N., Chen Y., Sun Q., Tang Y., Palmer D. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am. J. Hum. Genet. 2012;90:836–846.
    1. Nagamani S.C., Erez A., Lee B. Argininosuccinate lyase deficiency. Genet. Med. 2012;14:501–507.
    1. Ogawa M., Fujita Y., Niwa M., Takami N., Ozaki M. Role on blood pressure regulation of noradrenergic neurons originating from the locus coeruleus in the Kyoto-Wistar rat [proceedings] Jpn. Heart J. 1977;18:586–587.
    1. Paxinos G., Franklin K.B.J. 2nd Edition. Academic Press; San Diego: 2001. The Mouse Brain in Stereotaxic Coordinates.
    1. Samuels E.R., Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr. Neuropharmacol. 2008;6:235–253.
    1. Sanchez-Padilla J., Guzman J.N., Ilijic E., Kondapalli J., Galtieri D.J., Yang B., Schieber S., Oertel W., Wokosin D., Schumacker P.T., Surmeier D.J. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 2014;17:832–840.
    1. Saran R.K., Sahuja R.C., Gupta N.N., Hasan M., Bhargava K.P., Shanker K., Kishor K. 3-Methoxy-4-hydroxyphenylglycol in cerebrospinal fluid and vanillylmandelic acid in urine of humans with hypertension. Science. 1978;200:317–318.
    1. Szot P., Weinshenker D., White S.S., Robbins C.A., Rust N.C., Schwartzkroin P.A., Palmiter R.D. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J. Neurosci. 1999;19:10985–10992.
    1. Tait D.S., Brown V.J., Farovik A., Theobald D.E., Dalley J.W., Robbins T.W. Lesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat. Eur. J. Neurosci. 2007;25:3719–3724.
    1. Tekin I., Roskoski R., Jr., Carkaci-Salli N., Vrana K.E. Complex molecular regulation of tyrosine hydroxylase. J. Neural Transm. (Vienna) 2014;121:1451–1481.
    1. Tuchman M., McCullough B.A., Yudkoff M. The molecular basis of ornithine transcarbamylase deficiency. Eur. J. Pediatr. 2000;159(Suppl 3):S196–S198.
    1. Tuchman M., Lee B., Lichter-Konecki U., Summar M.L., Yudkoff M., Cederbaum S.D., Kerr D.S., Diaz G.A., Seashore M.R., Lee H.S., Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab. 2008;94:397–402.
    1. Volk N., Pape J.C., Engel M., Zannas A.S., Cattane N., Cattaneo A., Binder E.B., Chen A. Amygdalar microRNA-15a is essential for coping with chronic stress. Cell Rep. 2016;17:1882–1891.
    1. Wang Y., Sung C.C., Chung K.K. Novel enhancement mechanism of tyrosine hydroxylase enzymatic activity by nitric oxide through S-nitrosylation. Sci. Rep. 2017;7:44154.
    1. Westmark C.J., Westmark P.R., Beard A.M., Hildebrandt S.M., Malter J.S. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int. J. Clin. Exp. Pathol. 2008;1:157–168.
    1. Xu Z.Q., Pieribone V.A., Zhang X., Grillner S., Hökfelt T. A functional role for nitric oxide in locus coeruleus: immunohistochemical and electrophysiological studies. Exp. Brain Res. 1994;98:75–83.
    1. Xu R., Serritella A.V., Sen T., Farook J.M., Sedlak T.W., Baraban J., Snyder S.H., Sen N. Behavioral effects of cocaine mediated by nitric oxide-GAPDH transcriptional signaling. Neuron. 2013;78:623–630.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel